Role of gut pathogens in development of irritable bowel syndrome

Indian Journal of Medical Research

Volumn 139, Issue , 2014, Pages 11-18

  Grover, Madhusudan ^a  

^a MAYO CLINIC   (United States)

Author keywords

Campylobacter jejuni; Functional GI disorders; Infectious gastroenteritis; Post infectious irritable bowel syndrome; Rritable bowel syndrome

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; CALPAIN; CATECHOLAMINE; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESALAZINE; MONOCYTE CHEMOTACTIC PROTEIN 4; PREDNISOLONE; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; AGE; ANTIGEN PRESENTATION; ANXIETY; BLOATING; CYTOKINE RESPONSE; DEPRESSION; DISEASE SEVERITY; ENTERITIS; GASTROINTESTINAL DISEASE; GENDER; GENE EXPRESSION; HUMAN; IMMUNE DYSREGULATION; IRRITABLE COLON; PATHOPHYSIOLOGY; PHENOTYPE; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SMOKING; SOMATIZATION; VIRULENCE; CAMPYLOBACTER JEJUNI; GASTROENTERITIS; GASTROINTESTINAL TRACT; INFECTION; IRRITABLE BOWEL SYNDROME; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY;

ANTI-BACTERIAL AGENTS; CAMPYLOBACTER JEJUNI; GASTROENTERITIS; GASTROINTESTINAL TRACT; HUMANS; INFECTION; IRRITABLE BOWEL SYNDROME; RISK FACTORS;

EID: 84896829195     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Riddle MS, Murray JA, Porter CK. The incidence and risk of celiac disease in a healthy US adult population. Am J Gastroenterol 2012; 107: 1248-55.
2. Porter CK, Tribble DR, Aliaga PA, Halvorson HA, Riddle MS. Infectious gastroenteritis and risk of developing inflammatory bowel disease. Gastroenterology 2008; 135: 781-6.
3. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009; 136: 1979-88.
4. Chaudhary NA, Truelove SC. The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases. Q J Med 1962; 31: 307-22.
5. Ilnyckyj A, Balachandra B, Elliott L, Choudhri S, Duerksen DR. Post-traveler's diarrhea irritable bowel syndrome: a prospective study. Am J Gastroenterol 2003; 98: 596-9.
6. Porter CK, Gloor K, Cash BD, Riddle MS. Risk of functional gastrointestinal disorders in U.S. military following self-reported diarrhea and vomiting during deployment. Dig Dis Sci 2011; 56: 3262-9.
7. Riddle MS, Gutierrez RL, Verdu EF, Porter CK. The chronic gastrointestinal consequences associated with Campylobacter. Curr Gastroenterol Rep 2012; 14: 395-405.
8. Marshall JK, Thabane M, Borgaonkar MR, James C. Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 2007; 5: 457-60.
9. Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM; Walkerton Health Study Investigators. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 2010; 59: 605-11.
10. Schwille-Kiuntke J, Enck P, Zendler C, Krieg M, Polster AV, Klosterhalfen S, et al. Postinfectious irritable bowel syndrome: follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or Campylobacter. Neurogastroenterol Motil 2011; 23: e479-88.
11. Thabane M, Simunovic M, Akhtar-Danesh N, Marshall JK. Development and validation of a risk score for post-infectious irritable bowel syndrome. Am J Gastroenterol 2009; 104: 2267-74.
12. Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM; Walkerton Health Study Investigators. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006; 131: 445-50.
13. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome - a meta-analysis. Am J Gastroenterol 2006; 101: 1894-9.
14. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997; 314: 779-82.
15. Moss-Morris R, Spence M. To "lump" or to "split" the functional somatic syndromes: can infectious and emotional risk factors differentiate between the onset of chronic fatigue syndrome and irritable bowel syndrome? Psychosom Med 2006; 68: 463-9.
16. Mearin F, Perez-Oliveras M, Perello A, Vinyet J, Ibanez A, Coderch J, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterol 2005; 129: 98-104.
17. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterol 2003; 125: 1651-9.
18. Stermer E, Lubezky A, Potasman I, Paster E, Lavy A. Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study. Clin Infect Dis 2006; 43: 898-901.
19. Gwee KA, Graham JC, McKendrick MW, Collins SM, Marshall JS, Walters SJ, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 1996; 347: 150-3.
20. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53: 1096-101.
21. Thornley JP, Jenkins D, Neal K, Wright T, Brough J, Spiller RC. Relationship of Campylobacter toxigenicity in vitro to the development of postinfectious irritable bowel syndrome. J Infect Dis 2001; 184: 606-9.
22. Zanini B, Ricci C, Bandera F, Caselani F, Magni A, Laronga AM, et al; San Felice del Benaco Study Investigators. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol 2012; 107: 891-9.
23. Ji S, Park H, Lee D, Song YK, Choi JP, Lee SI. Post-infectious irritable bowel syndrome in patients with Shigella infection. J Gastroenterol Hepatol 2005; 20: 381-6.
24. McKendrick MW, Read NW. Irritable bowel syndrome - post salmonella infection. J Infect 1994; 29: 1-3.
25. Sethi S, Garey KW, Arora V, Ghantoji S, Rowan P, Smolensky M, et al. Increased rate of irritable bowel syndrome and functional gastrointestinal disorders after Clostridium difficile infection. J Hosp Infect 2011; 77: 172-3.
26. Piche T, Vanbiervliet G, Pipau FG, Dainese R, Hebuterne X, Rampal P, et al. Low risk of irritable bowel syndrome after Clostridium difficile infection. Can J Gastroenterol 2007; 21: 727-31.
27. Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 2002; 51: 410-3.
28. Saps M, Pensabene L, Di Martino L, Staiano A, Wechsler J, Zheng X, et al. Post-infectious functional gastrointestinal disorders in children. J Pediatr 2008; 152: 812-6.
29. Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 1999; 318: 565-6.
30. Dizdar V, Gilja OH, Hausken T. Increased visceral sensitivity in Giardia-induced postinfectious irritable bowel syndrome and functional dyspepsia. Effect of the 5HT3-antagonist ondansetron. Neurogastroenterol Motil 2007; 19: 977-82.
31. Soyturk M, Akpinar H, Gurler O, Pozio E, Sari I, Akar S, et al. Irritable bowel syndrome in persons who acquired trichinellosis. Am J Gastroenterol 2007; 102: 1064-9.
32. Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 2004; 99: 1774-8.
33. Borgaonkar MR, Ford DC, Marshall JK, Churchill E, Collins SM. The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection. Dig Dis Sci 2006; 51: 1026-32.
34. Porter CK, Gormley R, Tribble DR, Cash BD, Riddle MS. The incidence and gastrointestinal infectious risk of functional gastrointestinal disorders in a healthy US adult population. Am J Gastroenterol 2011; 106: 130-8.
35. Tuteja AK, Talley NJ, Gelman SS, Alder SC, Thompson C, Tolman K, et al. Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA. Dig Dis Sci 2008; 53: 271-6.
36. Cumberland P, Sethi D, Roderick PJ, Wheeler JG, Cowden JM, Roberts JA, et al. The infectious intestinal disease study of England: a prospective evaluation of symptoms and health care use after an acute episode. Epidemiol Infect 2003; 130: 453-60.
37. Parry SD, Stansfield R, Jelley D, Gregory W, Phillips E, Barton JR, et al. Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective, community-based, case-control study. Am J Gastroenterol 2003; 98: 1970-5.
38. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44: 400-6.
39. Parry SD, Barton JR, Welfare MR. Factors associated with the development of post-infectious functional gastrointestinal diseases: does smoking play a role? Eur J Gastroenterol Hepatol 2005; 17: 1071-5.
40. Barbara G, Stanghellini V, Berti-Ceroni C, De Giorgio R, Salvioli B, Corradi F, et al. Role of antibiotic therapy on long-term germ excretion in faeces and digestive symptoms after Salmonella infection. Aliment Pharmacol Ther 2000; 14: 1127-31.
41. Spence MJ, Moss-Morris R. The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis. Gut 2007; 56: 1066-71.
42. Lyte M, Vulchanova L, Brown DR. Stress at the intestinal surface: catecholamines and mucosa-bacteria interactions. Cell Tissue Res 2011; 343: 23-32.
43. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterol 2006; 130: 1480-91.
44. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003; 98: 1578-83.
45. Thabane M, Simunovic M, Akhtar-Danesh N, Garg AX, Clark WF, Marshall JK. Clustering and stability of functional lower gastrointestinal symptom after enteric infection. Neurogastroenterol Motil 2012; 24: 546-52.
46. Porter CK, Faix DJ, Shiau D, Espiritu J, Espinosa BJ, Riddle MS. Postinfectious gastrointestinal disorders following norovirus outbreaks. Clin Infect Dis 2012; 55: 915-22.
47. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-11.
48. Kim HS, Lim JH, Park H, Lee SI. Increased immunoendocrine cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute Shigella infection - an observation in a small case control study. Yonsei Med J 2010; 51: 45-51.
49. Han W, Lu X, Jia X, Zhou T, Guo C. Soluble mediators released from PI-IBS patients' colon induced alteration of mast cell: involvement of reactive oxygen species. Dig Dis Sci 2012; 57: 311-9.
50. Han W, Wang Z, Lu X, Guo C. Protease activated receptor 4 status of mast cells in post infectious irritable bowel syndrome. Neurogastroenterol Motil 2012; 24: 113-9, e82.
51. Swan C, Duroudier NP, Campbell E, Zaitoun A, Hastings M, Dukes GE, et al. Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFalpha. Gut 2013; 62: 985-94.
52. Marshall JK, Thabane M, Garg AX, Clark W, Meddings J, Collins SM; WEL Investigators. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther 2004; 20: 1317-22.
53. Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006; 101: 1288-94.
54. Nielsen H, Steffensen R, Ejlertsen T. Risk and prognosis of campylobacteriosis in relation to polymorphisms of host inflammatory cytokine genes. Scand J Immunol 2012; 75: 449-54.
55. Gwee KA, Collins SM, Read NW, Rajnakova A, Deng Y, Graham JC, et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003; 52: 523-6.
56. Liebregts T, Adam B, Bredack C, Roth A, Heinzel S, Lester S, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-20.
57. Villani AC, Lemire M, Thabane M, Belisle A, Geneau G, Garg AX, et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010; 138: 1502-13.
58. Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 (Suppl 1): S1-35.
59. Dunlop SP, Jenkins D, Neal KR, Naesdal J, Borgaonker M, Collins SM, et al. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18: 77-84.
60. Bafutto M, Almeida JR, Leite NV, Oliveira EC, Gabriel-Neto S, Rezende-Filho J. Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine. Arq Gastroenterol 2011; 48: 36-40.
61. Tuteja AK, Fang JC, Al-Suqi M, Stoddard GJ, Hale DC. Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome - a pilot study. Scand J Gastroenterol 2012; 47: 1159-64.